The 2021 WHO Classification of CNS Tumors incorporates molecular criteria, including CDKN2A homozygous deletion and TERT promoter mutation, in the diagnosis of anaplastic (WHO grade 3) meningioma. This evidence concerns the gene TERT and meningioma.